Excelsior Biopharma Inc. (TPEX:6496)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
26.30
-0.20 (-0.75%)
At close: Feb 11, 2026

Excelsior Biopharma Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-183.17-98.71-91.01-33.76-15.65
Depreciation & Amortization
71.6870.9646.2226.0628.65
Loss (Gain) From Sale of Assets
0.65----
Loss (Gain) From Sale of Investments
----0.21
Loss (Gain) on Equity Investments
-2.18-0.25---
Stock-Based Compensation
0.280.330.260.04-
Provision & Write-off of Bad Debts
-2.562.250.98-3.674.47
Other Operating Activities
-1.82.816.750.785.53
Change in Accounts Receivable
-45.81-30.53-27.1782.26-35.87
Change in Inventory
17.75-85.65-28.716.0271.88
Change in Accounts Payable
-38.7842.43-16.92-49.79-18.52
Change in Other Net Operating Assets
45.22-3.44-25.15-32.4615.13
Operating Cash Flow
-138.72-99.8-134.755.4955.82
Operating Cash Flow Growth
----90.17%-89.28%
Capital Expenditures
-36.95-257.15-35.66-7.78-2.88
Sale of Property, Plant & Equipment
2.25----
Investment in Securities
11.45-55.5199.74-200-6.01
Other Investing Activities
-1.155.62-17.478.54-1.8
Investing Cash Flow
-24.4-307.03146.62-199.24-10.68
Short-Term Debt Issued
159.610.010.01--
Long-Term Debt Issued
-110---
Total Debt Issued
159.61110.010.01--
Short-Term Debt Repaid
--0.01-0.01--
Long-Term Debt Repaid
-51.97-53.98-317.23-13.73-12.64
Total Debt Repaid
-51.97-53.99-317.24-13.73-12.64
Net Debt Issued (Repaid)
107.6456.02-317.23-13.73-12.64
Repurchase of Common Stock
-----23.74
Common Dividends Paid
-----46.67
Other Financing Activities
0.740.98---
Financing Cash Flow
108.3856.99-317.23-13.73-83.04
Net Cash Flow
-54.74-349.84-305.36-207.49-37.9
Free Cash Flow
-175.67-356.95-170.41-2.352.95
Free Cash Flow Growth
-----89.60%
Free Cash Flow Margin
-19.56%-41.41%-22.09%-0.34%3.96%
Free Cash Flow Per Share
-3.81-7.74-3.71-0.051.14
Cash Interest Paid
-7.961.360.881.12
Cash Income Tax Paid
-8.368.388.283.46
Levered Free Cash Flow
-104.63-311.04-139.514.4359.32
Unlevered Free Cash Flow
-99.78-306.02-135.537.1562.16
Change in Working Capital
-21.62-77.19-97.9516.0332.61
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.